Sciwind has two Western partners for its obesity drug, but is open to more

June 12, 2026 05:00 AM EDTUpdated 06:35 AM DealsChinaGLP-1 drugs Sci­wind has two West­ern part­ners for its obe­si­ty drug, but is open to more Elizabeth Cairns Senior biopharma journalist Sci­wind Bio­sciences has al­ready li­censed its GLP-1 obe­si­ty drug ec­nog­lu­tide twice over — to Pfiz­er and Ver­di­va Bio — but it is not done yet. The Chi­nese … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER